Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct comparison of the two blockbuster medications

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.